EA201991690A1 - Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения - Google Patents

Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения

Info

Publication number
EA201991690A1
EA201991690A1 EA201991690A EA201991690A EA201991690A1 EA 201991690 A1 EA201991690 A1 EA 201991690A1 EA 201991690 A EA201991690 A EA 201991690A EA 201991690 A EA201991690 A EA 201991690A EA 201991690 A1 EA201991690 A1 EA 201991690A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
proposed
methods
treatment
administering
Prior art date
Application number
EA201991690A
Other languages
English (en)
Inventor
Андрей ГУДКОВ
Катерина Леонова
Original Assignee
Хелт Рисерч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хелт Рисерч, Инк. filed Critical Хелт Рисерч, Инк.
Publication of EA201991690A1 publication Critical patent/EA201991690A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

Предложены подходы к противораковому и противовозрастному лечению путем введения ингибиторов активности обратной транскриптазы (RT), которые выполняют функцию ингибирования RT, кодируемой ORF2 LINE1, или любой RT, которая может участвовать в активации транскрипции ретроэлементов. Также предложены подходы к открытию новых соединений, которые могут ингибировать RT. Эти способы применимы для использования в популяциях раковых клеток, предраковых клеток и соматических клеток. Предложены способы мониторинга эффективности лечения, при котором ингибируется развитие устойчивости к фармацевтическим агентам, способы профилактики и/или терапии патологии, коррелирующей с накоплением соматических клеток, способных к спонтанной генерации генетических изменений независимо от клеточных делений. Предложены способы лечения и/или предотвращения возрастных состояний у индивидуума путем введения агента, способного избирательно уничтожать клетки, которые проявляют генетическую нестабильность. Предложены способы сенсибилизации раковых клеток к химиотерапевтическому агенту путем введения ингибитора RT.
EA201991690A 2017-01-23 2018-01-23 Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения EA201991690A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449380P 2017-01-23 2017-01-23
PCT/US2018/014806 WO2018136920A1 (en) 2017-01-23 2018-01-23 Inhibition of endogenous reverse transcriptase and targeting of cells for prophylaxis and therapy of cancer and aging

Publications (1)

Publication Number Publication Date
EA201991690A1 true EA201991690A1 (ru) 2019-12-30

Family

ID=62908374

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991690A EA201991690A1 (ru) 2017-01-23 2018-01-23 Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения

Country Status (9)

Country Link
US (1) US20210353706A1 (ru)
EP (1) EP3571297A4 (ru)
JP (1) JP2020514312A (ru)
KR (1) KR20190122679A (ru)
CN (1) CN110418840A (ru)
AU (1) AU2018210001A1 (ru)
CA (1) CA3051122A1 (ru)
EA (1) EA201991690A1 (ru)
WO (1) WO2018136920A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3125991A1 (en) * 2019-01-25 2020-07-30 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
CN114657281A (zh) * 2020-12-22 2022-06-24 中国科学院动物研究所 内源病毒作为衰老程度的标志物及其作为衰老干预靶标的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008743A1 (en) * 1989-12-08 1991-06-27 City Of Hope Circumvention of human tumor drug resistance
GB9217998D0 (en) * 1992-08-24 1992-10-07 Wellcome Found Methods of treating cancer
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
US20100130439A1 (en) * 2007-04-26 2010-05-27 Romesberg Floyd E Genomic mutation inhibitors that inhibit y family dna polymerases
US20110086869A1 (en) * 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102058525A (zh) * 2009-11-13 2011-05-18 天津金世制药有限公司 一种拉米夫定注射制剂及其制备方法
US20150219662A1 (en) * 2012-06-28 2015-08-06 University Of Louisville Research Foundation, Inc. Use of protein line-1 orf-1 as a biomarker for cancer
US9468646B2 (en) * 2013-01-23 2016-10-18 Alienor Farma Increased dosage of efavirenz for the treatment of cancer
JP6391561B2 (ja) * 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物
FR3027804A1 (fr) * 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
CN105147709B (zh) * 2015-07-20 2018-08-24 福建广生堂药业股份有限公司 一种替诺福韦二吡呋酯或其药用盐的用途

Also Published As

Publication number Publication date
KR20190122679A (ko) 2019-10-30
CN110418840A (zh) 2019-11-05
AU2018210001A1 (en) 2019-08-01
EP3571297A4 (en) 2020-08-26
US20210353706A1 (en) 2021-11-18
EP3571297A1 (en) 2019-11-27
CA3051122A1 (en) 2018-07-26
WO2018136920A1 (en) 2018-07-26
JP2020514312A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
EA201991690A1 (ru) Ингибирование эндогенной обратной транскриптазы и таргетирование клеток для профилактики и терапии рака и старения
PH12018502355A1 (en) Enzyme inhibitors
EA202190630A1 (ru) Способы комбинированной терапии
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
EA201600236A1 (ru) Производные 1,2,4-оксадиазола в качестве иммуномодуляторов
PH12015502549B1 (en) Heterocyclic derivatives
EA201291309A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
EA201991622A1 (ru) Комплексная терапия для лечения рака
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2020004374A (es) Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
JP2017534583A5 (ru)
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
Sriraksa et al. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma-cell line findings
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2022000545A (es) Inhibidores de enzimas.
PH12019502402A1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом